Jazz Pharmaceuticals

Jazz Pharmaceuticals is a global biopharmaceutical company founded in 2003 that specializes in developing and commercializing innovative medicines for patients with serious diseases. The company maintains a focused therapeutic portfolio, primarily targeting complex areas such as neuroscience, including sleep medicine and movement disorders, alongside oncology, which encompasses hematologic malignancies and solid tumors. By leveraging internal R&D, strategic acquisitions, and licensing partnerships, Jazz Pharmaceuticals addresses critical unmet medical needs for patients worldwide.

Operating with a workforce of 1,000-5,000 employees, the organization maintains a robust global footprint across 10 locations, including key facilities in the U.S., UK, Ireland, and Italy. The company’s operational structure supports a diverse pipeline of specialty biopharmaceutical products designed to improve patient outcomes. Meet Jazz Pharmaceuticals's team to learn about the leadership and organizational structure driving these advancements in medical science and patient care.

Publicly traded on the NASDAQ under the ticker JAZZ, the company demonstrates significant market presence within the healthcare sector. With annual revenue reaching $4.6B, Jazz Pharmaceuticals continues to scale its operations and expand its therapeutic reach. Explore financial highlights for detailed metrics regarding the company's fiscal performance, funding history, and long-term growth strategy in the competitive biopharmaceutical landscape.